Publications

Identification of Debio 0432 as a potent and selective USP1 Inhibitor for Cancer Therapy

Anti-Tumor Activity of Debio 0123 in Combination with Sacituzumab Govitecan in Preclinical Models of Breast Cancer

Impact of food and high gastric pH on the bioavailability of the WEE1 inhibitor Debio 0123 assessed in a phase…

Preclinical Characterization of DPI-4452: A 68Ga/177Lu Theranostic Ligand for Carbonic Anhydrase IX

First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX–Targeting Peptide, [68Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma

Debio 0123, a selective, brain penetrant WEE1 inhibitor in clinical development for patients with solid tumors

Debio 1562M, a next generation Antibody Drug Conjugate (ADC) targeting CD37 for AML and MDS treatment

A Phase 1/2 study of the WEE1 inhibitor Debio 0123 in combination with temozolomide +/– radiotherapy in adults with recurrent…

The Multilink(TM) Linker is a promising approach to improve efficacy and safety of ADC’s